TAS-200 Study in Muscle-Invasive Bladder Cancer Discontinued
The phase 3 SunRISe-2 trial (NCT04658862) has been discontinued, in which TAS-200 plus cetrelimab vs chemoradiation was being assessed in patients with muscle-invasive bladder cancer (MIBC), according to a press release from Johnson & Johnson.1 …